Second Revision of the International Staging System (R2-ISS) published by European Myeloma Network (EMN) in October 2022 incorporated del(17p), f(4:14) and 1q+ as the adverse prognostic chromosomal abnormalities and delete t(14;16). However the authors forgot to describe the scoring system: Which adverse prognostic factors get how many points? ascopubs.org/doi/full/10.1200/JCO.21.02614 R2-ISS, it helps predict both progression-free survival (PFS) and overall survival (OS) in patients with MM. According to data on 7072 patients at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. The R2-ISS stratifies patients into 4 risk groups according to the total additive score: low (0 points), low-intermediate (0.5-1 points), intermediate-high (1.5-2.5 points), high (3-5 points). Median OS and PFS: Low risk: not reached; 68 months Low-intermediate: 109.2 months; 45.5 Intermediate-High: 68.5; 30.2 High risk: 37.9 months; 19.9 months
I'm an internal Medicine resident rotating through hematology and I love your Lecturers Dr Kim. You simply hematology.🙏🏾
Can kappa light chains and kappa/lambda ratio increase in chronic inflammatory conditions and/or infection ? (M spike absent)
That was a very informative and excellent presentation to help patients, their families and professionals.
Second Revision of the International Staging System (R2-ISS) published by European Myeloma Network (EMN) in October 2022 incorporated del(17p), f(4:14) and 1q+ as the adverse prognostic chromosomal abnormalities and delete t(14;16).
However the authors forgot to describe the scoring system: Which adverse prognostic factors get how many points?
ascopubs.org/doi/full/10.1200/JCO.21.02614
R2-ISS, it helps predict both progression-free survival (PFS) and overall survival (OS) in patients with MM. According to data on 7072 patients at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. The R2-ISS stratifies patients into 4 risk groups according to the total additive score: low (0 points), low-intermediate (0.5-1 points), intermediate-high (1.5-2.5 points), high (3-5 points).
Median OS and PFS:
Low risk: not reached; 68 months
Low-intermediate: 109.2 months; 45.5
Intermediate-High: 68.5; 30.2
High risk: 37.9 months; 19.9 months